# A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

> **NCT05305664** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 51 (actual)

## Conditions studied

- Hyperlipoproteinemia(a)

## Interventions

- **DRUG:** Pelacarsen (TQJ230) 80 mg s.c.
- **DRUG:** Corresponding Placebo

## Key facts

- **NCT ID:** NCT05305664
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-19
- **Primary completion:** 2025-01-28
- **Final completion:** 2025-01-28
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05305664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05305664, "A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05305664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*